BioSpring.Ltd – Healing Beyond Borders
  • Home
  • About Us
  • Our Focus
    • Press Release
    • Global Market
    • Product Pipeline
  • Manufacturing
  • Product Verify
  • Contact Us
  • Home
  • About Us
  • Our Focus
    • Press Release
    • Global Market
    • Product Pipeline
  • Manufacturing
  • Product Verify
  • Contact Us
Product Pipeline
  • All Categories
  • Our Focus
    • Product Pipeline
    • Global Market
    • Press Release
Tag
  • All Tags
  • PRnews
  • Generic Drug
Order By ID
  • Default
  • Order By Date
  • Order By Title
  • Order By ID
  • BioSpring launches Bioscovy for PrEP in global market

    BioSpring launches Bioscovy for PrEP in global market

    Product Pipeline 09.20.2022 220 Views

    September 20, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching Bioscovy (emtricitabine 200mg/ tenofovir alafenamide 25mg) tablet for customers, each box of Bioscovy includes 30 tablets. It is a tablet taken by mouth.  Bioscovy for PrEP (pre-exposure prophylaxis) is a once-daily prescription medicine for adults and adolescents at risk of HIV. Bioscovy for PrEP is not for everyone: It is not…

  • BioSpring launches BIOPALB for HR+/HER2- mBC breast cancer in global market

    BioSpring launches BIOPALB for HR+/HER2- mBC breast cancer in global market

    Product Pipeline 10.05.2022 225 Views

    October 05, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOPALB (Palbociclib 125mg) capsules are indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (mBC) in combination with: an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or fulvestrant in patients…

  • BioSpring Launches Oral Psoriasis Therapy BIODEUCRA for Global Market Clients

    BioSpring Launches Oral Psoriasis Therapy BIODEUCRA for Global Market Clients

    Product Pipeline 10.06.2022 440 Views

    October 06, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIODEUCRA (Deucravacitinib 6mg) tablets for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the first approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis…

  • BioSpring Launches BIOMOB to treat EGFR Ex20ins mutated lung cancer for Global Market Clients

    BioSpring Launches BIOMOB to treat EGFR Ex20ins mutated lung cancer for Global Market Clients

    Product Pipeline 11.07.2022 195 Views

    November 07, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOMOB (Mobocertinib 40mg) capsules for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) mutation. Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region.Mobocertinib is an irreversible kinase inhibitor, forming a covalent…

  • BioSpring Launches BIOVENTOC to treat the treatment of chronic lymphocytic leukemia (CLL) for Global Market Clients

    BioSpring Launches BIOVENTOC to treat the treatment of chronic lymphocytic leukemia (CLL) for Global Market Clients

    Product Pipeline 03.21.2023 15 Views

    November 20, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOVENTOC venetoclax 100mg) tablets for the treatment ofchronic lymphocytic leukemia (CLL) . Venetoclax (brand name Venclexta) is a prescription medication used for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). It is an oral small molecule inhibitor that targets the B-cell…

  • BioSpring Launches BIOTRAME & BIODABRA to treat  mutated lung cancer for Global Market Clients

    BioSpring Launches BIOTRAME & BIODABRA to treat mutated lung cancer for Global Market Clients

    Product Pipeline 03.21.2023 12 Views

    Trametinib and dabrafenib are prescription medications used in combination to treat a specific type of skin cancer called melanoma that has a specific mutation called BRAF V600E or V600K. Dabrafenib is a selective inhibitor of mutated BRAF kinases, which are involved in cell growth and survival. Trametinib is a selective inhibitor of MEK, which is a downstream target of BRAF…

BioSpring.Ltd – Healing Beyond Borders

Our world-class finished dose manufacturing facility is located in the middle of the best industrial development areas in Laos [Saysetteha Development Zone]. The factory has specialized manufacturing modules for oral solid dose tablets, capsules, injections and caters to both export and domestic markets.

  • Our Focus
    • Press Release
    • Global Market
    • Product Pipeline
  • About Us
    • Manufacturing
    • Product Verify
    • Contact Us

Follow Us

  • LienTeh
  • Eeinpresswire

Copyright © 2022. BioSpring.LTD. All rights reserved.

Privacy Policy Terms & Conditions